Fig. 1From: Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy aloneMRI abdomen T2-hyperintense signal. a & b showing multiple metastatic lesions to the liver before the initiation of immunotherapy. c showing progression of the disease after 4Â cycles of nivolumab. The largest lesion was 5.5Â cm in the right hepatic lobe. d showing a mixed response after 4Â cycles on ipilimumab/nivolumabBack to article page